Search

Your search keyword '"Goldstein, Lori J."' showing total 425 results
Start Over Author "Goldstein, Lori J."

Refine your results

more »

more »

more »

more »
425 results on '"Goldstein, Lori J."'

3. Computational pathology improves risk stratification of a multi-gene assay for early stage ER+ breast cancer

Author

Chen, Yuli, Li, Haojia, Janowczyk, Andrew, Toro, Paula, Corredor, Germán, Whitney, Jon, Lu, Cheng, Koyuncu, Can F., Mokhtari, Mojgan, Buzzy, Christina, Ganesan, Shridar, Feldman, Michael D., Fu, Pingfu, Corbin, Haley, Harbhajanka, Aparna, Gilmore, Hannah, Goldstein, Lori J., Davidson, Nancy E., Desai, Sangeeta, Parmar, Vani, and Madabhushi, Anant

Published
2023
Full Text
View/download PDF

6. Recurrence score gene axes scores and outcomes by race and ethnicity in the RxPONDER trial.

Author

Abdou, Yara, primary, Hoag, Jess R, additional, Barlow, William E., additional, Gralow, Julie R., additional, Meric-Bernstam, Funda, additional, Albain, Kathy S., additional, Hayes, Daniel F., additional, Lin, Nancy U., additional, Perez, Edith A., additional, Goldstein, Lori J., additional, Chia, Stephen K. L., additional, Dhesy-Thind, Sukhbinder K., additional, Rastogi, Priya, additional, Schott, Anne F., additional, Racz, Jennifer M., additional, Tripathy, Debashish, additional, Hortobagyi, Gabriel N., additional, Pusztai, Lajos, additional, Sharma, Priyanka, additional, and Kalinsky, Kevin, additional

Published
2024
Full Text
View/download PDF

7. Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER).

Author

Kalinsky, Kevin, primary, Barlow, William E., additional, Pathak, Harsh B, additional, Gralow, Julie R., additional, Albain, Kathy S., additional, Hayes, Daniel F., additional, Lin, Nancy U., additional, Perez, Edith A., additional, Goldstein, Lori J., additional, Chia, Stephen K. L., additional, Rastogi, Priya, additional, Schott, Anne F., additional, Shak, Steven, additional, Tripathy, Debashish, additional, Hortobagyi, Gabriel N., additional, Meric-Bernstam, Funda, additional, Sharma, Priyanka, additional, Pusztai, Lajos, additional, Thompson, Alastair Mark, additional, and Godwin, Andrew K., additional

Published
2024
Full Text
View/download PDF

8. Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230.

Author

Moore, Halle CF, Unger, Joseph M, Phillips, Kelly-Anne, Boyle, Frances, Hitre, Erika, Moseley, Anna, Porter, David J, Francis, Prudence A, Goldstein, Lori J, Gomez, Henry L, Vallejos, Carlos S, Partridge, Ann H, Dakhil, Shaker R, Garcia, Agustin A, Gralow, Julie R, Lombard, Janine M, Forbes, John F, Martino, Silvana, Barlow, William E, Fabian, Carol J, Minasian, Lori M, Meyskens, Frank L, Gelber, Richard D, Hortobagyi, Gabriel N, and Albain, Kathy S

Subjects
Cancer, Aging, Clinical Trials and Supportive Activities, Breast Cancer, Contraception/Reproduction, Estrogen, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Reproductive health and childbirth, Good Health and Well Being, Adult, Anthracyclines, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Cyclophosphamide, Female, Follow-Up Studies, Goserelin, Humans, Menopause, Premature, Middle Aged, Pregnancy, Pregnancy Outcome, Primary Ovarian Insufficiency, Receptors, Estrogen, Survival Rate, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Premature menopause is a serious long-term side effect of chemotherapy. We evaluated long-term pregnancy and disease-related outcomes for patients in S0230/POEMS, a study in premenopausal women with stage I-IIIA estrogen receptor-negative, progesterone receptor-negative breast cancer to be treated with cyclophosphamide-containing chemotherapy. Women were randomly assigned to standard chemotherapy with or without goserelin, a gonadotropin-releasing hormone agonist, and were stratified by age and chemotherapy regimen. All statistical tests were two-sided. Of 257 patients, 218 were eligible and evaluable (105 in the chemotherapy + goserelin arm and 113 in the chemotherapy arm). More patients in the chemotherapy + goserelin arm reported at least one pregnancy vs the chemotherapy arm (5-year cumulative incidence = 23.1%, 95% confidence interval [CI] = 15.3% to 31.9%; and 12.2%, 95% CI = 6.8% to 19.2%, respectively; odds ratio = 2.34; 95% CI = 1.07 to 5.11; P = .03). Randomization to goserelin + chemotherapy was associated with a nonstatistically significant improvement in disease-free survival (hazard ratio [HR] = 0.55; 95% CI = 0.27 to 1.10; P = .09) and overall survival (HR = 0.45; 95% CI = 0.19 to 1.04; P = .06). In this long-term analysis of POEMS/S0230, we found continued evidence that patients randomly assigned to receive goserelin + chemotherapy were not only more likely to avoid premature menopause, but were also more likely to become pregnant without adverse effect on disease-related outcomes.

Published
2019

10. Goserelin for Ovarian Protection During Breast-Cancer Adjuvant Chemotherapy

Author

Moore, Halle CF, Unger, Joseph M, Phillips, Kelly-Anne, Boyle, Frances, Hitre, Erika, Porter, David, Francis, Prudence A, Goldstein, Lori J, Gomez, Henry L, Vallejos, Carlos S, Partridge, Ann H, Dakhil, Shaker R, Garcia, Agustin A, Gralow, Julie, Lombard, Janine M, Forbe, John F, Martino, Silvana, Barlow, William E, Fabian, Carol J, Minasian, Lori, Meyskens, Frank L, Gelber, Richard D, Hortobagyi, Gabriel N, and Albain, Kathy S

Subjects
Clinical Trials and Supportive Activities, Contraception/Reproduction, Aging, Rare Diseases, Breast Cancer, Clinical Research, Cancer, Estrogen, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Reproductive health and childbirth, Paediatrics and Reproductive Medicine, Obstetrics & Reproductive Medicine
Published
2015

11. Risk of Marrow Neoplasms After Adjuvant Breast Cancer Therapy: The National Comprehensive Cancer Network Experience

Author

Wolff, Antonio C, Blackford, Amanda L, Visvanathan, Kala, Rugo, Hope S, Moy, Beverly, Goldstein, Lori J, Stockerl-Goldstein, Keith, Neumayer, Leigh, Langbaum, Terry S, Theriault, Richard L, Hughes, Melissa E, Weeks, Jane C, and Karp, Judith E

Subjects
Clinical Research, Prevention, Hematology, Breast Cancer, Cancer, Patient Safety, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Bone Marrow Neoplasms, Breast Neoplasms, Cohort Studies, Databases, Factual, Female, Follow-Up Studies, Humans, Incidence, Mastectomy, Middle Aged, Neoplasm Staging, Outcome Assessment, Health Care, Radiotherapy, Risk Factors, SEER Program, Survival Analysis, United States, Young Adult, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeOutcomes for early-stage breast cancer have improved. First-generation adjuvant chemotherapy trials reported a 0.27% 8-year cumulative incidence of myelodysplastic syndrome/acute myelogenous leukemia. Incomplete ascertainment and follow-up may have underestimated subsequent risk of treatment-associated marrow neoplasm (MN).Patients and methodsWe examined the MN frequency in 20,063 patients with stage I to III breast cancer treated at US academic centers between 1998 and 2007. Time-to-event analyses were censored at first date of new cancer event, last contact date, or death and considered competing risks. Cumulative incidence, hazard ratios (HRs), and comparisons with Surveillance, Epidemiology, and End Results estimates were obtained. Marrow cytogenetics data were reviewed.ResultsFifty patients developed MN (myeloid, n = 42; lymphoid, n = 8) after breast cancer (median follow-up, 5.1 years). Patients who developed MN had similar breast cancer stage distribution, race, and chemotherapy exposure but were older compared with patients who did not develop MN (median age, 59.1 v 53.9 years, respectively; P = .03). Two thirds of patients had complex MN cytogenetics. Risk of MN was significantly increased after surgery plus chemotherapy (HR, 6.8; 95% CI, 1.3 to 36.1) or after all modalities (surgery, chemotherapy, and radiation; HR, 7.6; 95% CI, 1.6 to 35.8), compared with no treatment with chemotherapy. MN rates per 1,000 person-years were 0.16 (surgery), 0.43 (plus radiation), 0.46 (plus chemotherapy), and 0.54 (all three modalities). Cumulative incidence of MN doubled between years 5 and 10 (0.24% to 0.48%); 9% of patients were alive at 10 years.ConclusionIn this large early-stage breast cancer cohort, MN risk after radiation and/or adjuvant chemotherapy was low but higher than previously described. Risk continued to increase beyond 5 years. Individual risk of MN must be balanced against the absolute survival benefit of adjuvant chemotherapy.

Published
2015

13. Phase III trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH analog during chemotherapy (CT) to reduce ovarian failure in early-stage, hormone receptor-negative breast cancer: An international Intergroup trial of SWOG, IBCSG, ECOG, and CALGB (Alliance).

Author

Moore, Halle CF, Unger, Joseph M, Phillips, Kelly-Anne, Boyle, Frances M, Hitre, Erika, Porter, David James, Francis, Prudence A, Minasian, Lori M, Gelber, Richard D, Goldstein, Lori J, Gomez, Henry Leonidas, Vallejos, Carlos, Partridge, Ann H, Dakhil, Shaker R, Martino, Silvana, Barlow, William E, Fabian, Carol J, Meyskens, Frank L, Hortobagyi, Gabriel N, and Albain, Kathy S

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Aging, Clinical Trials and Supportive Activities, Cancer, Estrogen, Clinical Research, Contraception/Reproduction, Breast Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Clinical Sciences, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

LBA505 Background: Premature ovarian failure (POF) is a common toxicity of CT. Risk depends on type and amount of CT, age, and perhaps ovarian cycling at the time of CT. POEMS is a SWOG-coordinated phase III randomized study to evaluate whether LHRH analog administration with CT for early-stage breast cancer (BC) would reduce POF.Premenopausal patients (PT) age .05). POF rates were 22% in the standard arm and 8% in the GN arm (OR=0.30, 95% CI: 0.10-0.87, p=.03 [unadjusted analysis]; OR=0.36, 95%CI: 0.11-1.14, p=0.08 [adjusted logistic regression analysis]). In a sensitivity analysis defining 2-year POF more liberally as either amenorrhea or elevated FSH, 45% in the standard arm and 20% in the GN arm had POF (OR=0.29, 95% CI: 0.12-0.70, p=.006). There were 13 pregnancies in the standard arm and 22 in the GN arm (OR=2.22, 95% CI: 1.00-4.92, p=.05). DFS and OS were better in the GN arm (Cox regression, including stage: HR=0.49, 95% CI: 0.24-0.97, p=.04; HR=0.43, 95% CI: 0.18-1.00, p=.05, respectively).LHRH analog administration with CT was associated with less POF and more pregnancies. In an exploratory analysis, GN use in premenopausal ER-negative BC was associated with improved DFS and OS.NCT00068601.

Published
2014

14. Phase III trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH analog during chemotherapy (CT) to reduce ovarian failure in early-stage, hormone receptor-negative breast cancer: An international Intergroup trial of SWOG, IBCSG, ECOG, and CALGB (Alliance).

Author

Unger, Joseph M, Phillips, Kelly-Anne, Boyle, Frances M, Hitre, Erika, Porter, David James, Francis, Prudence A, Minasian, Lori M, Gelber, Richard D, Goldstein, Lori J, Gomez, Henry Leonidas, Vallejos, Carlos, Partridge, Ann H, Dakhil, Shaker R, Martino, Silvana, Barlow, William E, Fabian, Carol J, Meyskens, Frank L, Hortobagyi, Gabriel N, and Albain, Kathy S

Subjects
Oncology & Carcinogenesis, Oncology and Carcinogenesis
Abstract

LBA505 Background: Premature ovarian failure (POF) is a common toxicity of CT. Risk depends on type and amount of CT, age, and perhaps ovarian cycling at the time of CT. POEMS is a SWOG-coordinated phase III randomized study to evaluate whether LHRH analog administration with CT for early-stage breast cancer (BC) would reduce POF.Premenopausal patients (PT) age .05). POF rates were 22% in the standard arm and 8% in the GN arm (OR=0.30, 95% CI: 0.10-0.87, p=.03 [unadjusted analysis]; OR=0.36, 95%CI: 0.11-1.14, p=0.08 [adjusted logistic regression analysis]). In a sensitivity analysis defining 2-year POF more liberally as either amenorrhea or elevated FSH, 45% in the standard arm and 20% in the GN arm had POF (OR=0.29, 95% CI: 0.12-0.70, p=.006). There were 13 pregnancies in the standard arm and 22 in the GN arm (OR=2.22, 95% CI: 1.00-4.92, p=.05). DFS and OS were better in the GN arm (Cox regression, including stage: HR=0.49, 95% CI: 0.24-0.97, p=.04; HR=0.43, 95% CI: 0.18-1.00, p=.05, respectively).LHRH analog administration with CT was associated with less POF and more pregnancies. In an exploratory analysis, GN use in premenopausal ER-negative BC was associated with improved DFS and OS.NCT00068601.

Published
2014

15. Supplementary Data Tables from Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study

Author

Turner, Nicholas C., primary, Balmaña, Judith, primary, Poncet, Coralie, primary, Goulioti, Theodora, primary, Tryfonidis, Konstantinos, primary, Honkoop, Aafke H., primary, Zoppoli, Gabriele, primary, Razis, Evangelia, primary, Johannsson, Oskar T., primary, Colleoni, Marco, primary, Tutt, Andrew N., primary, Audeh, William, primary, Ignatiadis, Michail, primary, Mailliez, Audrey, primary, Trédan, Olivier, primary, Musolino, Antonino, primary, Vuylsteke, Peter, primary, Juan-Fita, Maria Jose, primary, Macpherson, Iain R.J., primary, Kaufman, Bella, primary, Manso, Luis, primary, Goldstein, Lori J., primary, Ellard, Susan L., primary, Láng, István, primary, Jen, Kai Yu, primary, Adam, Virginie, primary, Litière, Saskia, primary, Erban, John, primary, and Cameron, David A., primary

Published
2023
Full Text
View/download PDF

16. Supplementary Data Investigator Lists from Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study

Author

Turner, Nicholas C., primary, Balmaña, Judith, primary, Poncet, Coralie, primary, Goulioti, Theodora, primary, Tryfonidis, Konstantinos, primary, Honkoop, Aafke H., primary, Zoppoli, Gabriele, primary, Razis, Evangelia, primary, Johannsson, Oskar T., primary, Colleoni, Marco, primary, Tutt, Andrew N., primary, Audeh, William, primary, Ignatiadis, Michail, primary, Mailliez, Audrey, primary, Trédan, Olivier, primary, Musolino, Antonino, primary, Vuylsteke, Peter, primary, Juan-Fita, Maria Jose, primary, Macpherson, Iain R.J., primary, Kaufman, Bella, primary, Manso, Luis, primary, Goldstein, Lori J., primary, Ellard, Susan L., primary, Láng, István, primary, Jen, Kai Yu, primary, Adam, Virginie, primary, Litière, Saskia, primary, Erban, John, primary, and Cameron, David A., primary

Published
2023
Full Text
View/download PDF

17. Supp Figure S1 from Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study

Author

Turner, Nicholas C., primary, Balmaña, Judith, primary, Poncet, Coralie, primary, Goulioti, Theodora, primary, Tryfonidis, Konstantinos, primary, Honkoop, Aafke H., primary, Zoppoli, Gabriele, primary, Razis, Evangelia, primary, Johannsson, Oskar T., primary, Colleoni, Marco, primary, Tutt, Andrew N., primary, Audeh, William, primary, Ignatiadis, Michail, primary, Mailliez, Audrey, primary, Trédan, Olivier, primary, Musolino, Antonino, primary, Vuylsteke, Peter, primary, Juan-Fita, Maria Jose, primary, Macpherson, Iain R.J., primary, Kaufman, Bella, primary, Manso, Luis, primary, Goldstein, Lori J., primary, Ellard, Susan L., primary, Láng, István, primary, Jen, Kai Yu, primary, Adam, Virginie, primary, Litière, Saskia, primary, Erban, John, primary, and Cameron, David A., primary

Published
2023
Full Text
View/download PDF

18. Data from Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study

Author

Turner, Nicholas C., primary, Balmaña, Judith, primary, Poncet, Coralie, primary, Goulioti, Theodora, primary, Tryfonidis, Konstantinos, primary, Honkoop, Aafke H., primary, Zoppoli, Gabriele, primary, Razis, Evangelia, primary, Johannsson, Oskar T., primary, Colleoni, Marco, primary, Tutt, Andrew N., primary, Audeh, William, primary, Ignatiadis, Michail, primary, Mailliez, Audrey, primary, Trédan, Olivier, primary, Musolino, Antonino, primary, Vuylsteke, Peter, primary, Juan-Fita, Maria Jose, primary, Macpherson, Iain R.J., primary, Kaufman, Bella, primary, Manso, Luis, primary, Goldstein, Lori J., primary, Ellard, Susan L., primary, Láng, István, primary, Jen, Kai Yu, primary, Adam, Virginie, primary, Litière, Saskia, primary, Erban, John, primary, and Cameron, David A., primary

Published
2023
Full Text
View/download PDF

23. Supplementary Table 1 from Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer

Author

Sparano, Joseph A., primary, Goldstein, Lori J., primary, Childs, Barrett H., primary, Shak, Steven, primary, Brassard, Diana, primary, Badve, Sunil, primary, Baehner, Frederick L., primary, Bugarini, Roberto, primary, Rowley, Steve, primary, Perez, Edith A., primary, Shulman, Lawrence N., primary, Martino, Silvana, primary, Davidson, Nancy E., primary, Kenny, Paraic A., primary, Sledge, George W., primary, and Gray, Robert, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Figure 1 from Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer

Author

Sparano, Joseph A., primary, Goldstein, Lori J., primary, Childs, Barrett H., primary, Shak, Steven, primary, Brassard, Diana, primary, Badve, Sunil, primary, Baehner, Frederick L., primary, Bugarini, Roberto, primary, Rowley, Steve, primary, Perez, Edith A., primary, Shulman, Lawrence N., primary, Martino, Silvana, primary, Davidson, Nancy E., primary, Kenny, Paraic A., primary, Sledge, George W., primary, and Gray, Robert, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Table 2 from Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer

Author

Sparano, Joseph A., primary, Goldstein, Lori J., primary, Childs, Barrett H., primary, Shak, Steven, primary, Brassard, Diana, primary, Badve, Sunil, primary, Baehner, Frederick L., primary, Bugarini, Roberto, primary, Rowley, Steve, primary, Perez, Edith A., primary, Shulman, Lawrence N., primary, Martino, Silvana, primary, Davidson, Nancy E., primary, Kenny, Paraic A., primary, Sledge, George W., primary, and Gray, Robert, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figure 2 from Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer

Author

Sparano, Joseph A., primary, Goldstein, Lori J., primary, Childs, Barrett H., primary, Shak, Steven, primary, Brassard, Diana, primary, Badve, Sunil, primary, Baehner, Frederick L., primary, Bugarini, Roberto, primary, Rowley, Steve, primary, Perez, Edith A., primary, Shulman, Lawrence N., primary, Martino, Silvana, primary, Davidson, Nancy E., primary, Kenny, Paraic A., primary, Sledge, George W., primary, and Gray, Robert, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Data from Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer

Author

Sparano, Joseph A., primary, Goldstein, Lori J., primary, Childs, Barrett H., primary, Shak, Steven, primary, Brassard, Diana, primary, Badve, Sunil, primary, Baehner, Frederick L., primary, Bugarini, Roberto, primary, Rowley, Steve, primary, Perez, Edith, primary, Shulman, Lawrence N., primary, Martino, Silvana, primary, Davidson, Nancy E., primary, Sledge, George W., primary, and Gray, Robert, primary

Published
2023
Full Text
View/download PDF

29. Supplementary Table 3 from Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer

Author

Sparano, Joseph A., primary, Goldstein, Lori J., primary, Childs, Barrett H., primary, Shak, Steven, primary, Brassard, Diana, primary, Badve, Sunil, primary, Baehner, Frederick L., primary, Bugarini, Roberto, primary, Rowley, Steve, primary, Perez, Edith A., primary, Shulman, Lawrence N., primary, Martino, Silvana, primary, Davidson, Nancy E., primary, Kenny, Paraic A., primary, Sledge, George W., primary, and Gray, Robert, primary

Published
2023
Full Text
View/download PDF

30. Abstract GS1-04: Patient-reported cognitive impairment in women participating in the RxPONDER trial (SWOG S1007) by menopausal status

Author

Kang, Irene, primary, Forschmiedt, Jamie K., additional, Loch, Michelle M., additional, Barlow, William E., additional, Lew, Danika L., additional, Gralow, Julie R., additional, Meric-Bernstam, Funda, additional, Albain, Kathy S., additional, Hayes, Daniel F., additional, Lin, Nancy U., additional, Perez, Edith A., additional, Goldstein, Lori J., additional, Rastogi, Priya, additional, Schott, Anne F., additional, Shak, Steven, additional, Sharma, Priyanka, additional, Miao, Jieling, additional, Tripathy, Debu, additional, Pusztai, Lajos, additional, Hortobagyi, Gabriel N., additional, Kalinsky, Kevin, additional, and Henry, N. Lynn, additional

Published
2023
Full Text
View/download PDF

31. Abstract GS1-01: Race and clinical outcomes in the RxPONDER Trial (SWOG S1007)

Author

Abdou, Yara, primary, Barlow, William E., additional, Gralow, Julie R., additional, Meric-Bernstam, Funda, additional, Albain, Kathy S., additional, Hayes, Daniel F., additional, Lin, Nancy U., additional, Perez, Edith A., additional, Goldstein, Lori J., additional, Chia, Stephen K., additional, Dhesy-Thind, Sukhbinder, additional, Rastogi, Priya, additional, Alba, Emilio, additional, Delaloge, Suzette, additional, Schott, Anne F., additional, Shak, Steven, additional, Sharma, Priyanka, additional, Lew, Danika L., additional, Miao, Jieling, additional, Unger, Joseph M., additional, Tripathy, Debu, additional, Pusztai, Lajos, additional, Hortobagyi, Gabriel N., additional, and Kalinsky, Kevin, additional

Published
2023
Full Text
View/download PDF

32. Abstract P6-05-06: Patient-reported anxiety and fatigue in women enrolled in the RxPONDER trial (SWOG S1007) by menopausal status

Author

Loch, Michelle M., primary, Forschmiedt, Jamie K., additional, Kang, Irene M., additional, Gralow, Julie R., additional, Meric-Bernstam, Funda, additional, Albain, Kathy S., additional, Hayes, Daniel F., additional, Lin, Nancy U., additional, Perez, Edith A., additional, Goldstein, Lori J., additional, Rastogi, Priya, additional, Schott, Anne F., additional, Shak, Steven, additional, Sharma, Priyanka, additional, Lew, Danika L., additional, Miao, Jieling, additional, Barlow, William E., additional, Tripathy, Debu, additional, Pusztai, Lajos, additional, Hortobagyi, Gabriel N., additional, Kalinsky, Kevin, additional, and Henry, N. Lynn, additional

Published
2023
Full Text
View/download PDF

33. A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104)

Author

Goldstein, Lori J., Zhao, Fengmin, Wang, Molin, Swaby, Ramona F., Sparano, Joseph A., Meropol, Neal J., Bhalla, Kapil N., Pellegrino, Christine M., Katherine Alpaugh, R., Falkson, Carla I., Klein, Paula, and Sledge, George W.

Published
2017
Full Text
View/download PDF

39. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

Author

Gradishar, William J., primary, Moran, Meena S., additional, Abraham, Jame, additional, Aft, Rebecca, additional, Agnese, Doreen, additional, Allison, Kimberly H., additional, Anderson, Bethany, additional, Burstein, Harold J., additional, Chew, Helen, additional, Dang, Chau, additional, Elias, Anthony D., additional, Giordano, Sharon H., additional, Goetz, Matthew P., additional, Goldstein, Lori J., additional, Hurvitz, Sara A., additional, Isakoff, Steven J., additional, Jankowitz, Rachel C., additional, Javid, Sara H., additional, Krishnamurthy, Jairam, additional, Leitch, Marilyn, additional, Lyons, Janice, additional, Mortimer, Joanne, additional, Patel, Sameer A., additional, Pierce, Lori J., additional, Rosenberger, Laura H., additional, Rugo, Hope S., additional, Sitapati, Amy, additional, Smith, Karen Lisa, additional, Smith, Mary Lou, additional, Soliman, Hatem, additional, Stringer-Reasor, Erica M., additional, Telli, Melinda L., additional, Ward, John H., additional, Wisinski, Kari B., additional, Young, Jessica S., additional, Burns, Jennifer, additional, and Kumar, Rashmi, additional

Published
2022
Full Text
View/download PDF

41. Prospective Comparison of Geriatric Assessment and Provider's Assessment of Older Adults With Metastatic Breast Cancer in the Community

Author

Seedor, Rino S, Meeker, Caitlin R, Lewis, Bianca, Handorf, Elizabeth A, Filchner, Kelly A, Varadarajan, Ramya, Hensold, Jack, Padmanabhan, Aruna, Negin, Benjamin, Blankstein, Kenneth, Chawla, Neha R, Song, Wei Frank, Epstein, Jessica, Winn, Jennifer, Goldstein, Lori J, Dotan, Efrat, Seedor, Rino S, Meeker, Caitlin R, Lewis, Bianca, Handorf, Elizabeth A, Filchner, Kelly A, Varadarajan, Ramya, Hensold, Jack, Padmanabhan, Aruna, Negin, Benjamin, Blankstein, Kenneth, Chawla, Neha R, Song, Wei Frank, Epstein, Jessica, Winn, Jennifer, Goldstein, Lori J, and Dotan, Efrat

Abstract

Background: Geriatric assessment (GA) is recommended for evaluating fitness of an older adult with cancer. Our objective was to prospectively evaluate the gaps that exist in the assessment of older adults with metastatic breast cancer (OA-MBC) in community practices (CP). Methods: Self-administered GA was compared to provider's assessment (PA) of patients living with MBC aged ≥65 years treated in CP Providers were blinded to the GA results until PA was completed. McNemar's test was used to detect differences between PA and GA. Results: One hundred patients were enrolled across 9 CP (median age 73.9). Geriatric assessment detected a total of 356 abnormalities in 96 patients; of which, 223 required interventions. African American and widowed/single patients were more likely to have abnormalities identified by GA. On average, across 100 patients, PA did not detect 25.5% of GA-detected abnormalities, mostly in functional status, social support, nutrition, and cognition. These differences were less pronounced among providers with more clinical experience. Patients with abnormal Timed Up and Go tests more likely had additional abnormalities in other domains, and more abnormalities that were not identified by PA. Providers were "surprised" by GA results in 33% of cases, mainly with cognitive or social support findings, and reported plans for management change for 39% of patients based on GA findings. Conclusions: Including a GA in the care of OA-MBC in CP is beneficial for the detection of multiple abnormalities not detected by routine PA.

Published
2022

43. Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (E2108)

Author

Khan, Seema A., primary, Zhao, Fengmin, additional, Goldstein, Lori J., additional, Cella, David, additional, Basik, Mark, additional, Golshan, Mehra, additional, Julian, Thomas B., additional, Pockaj, Barbara A., additional, Lee, Christine A., additional, Razaq, Wajeeha, additional, Sparano, Joseph A., additional, Babiera, Gildy V., additional, Dy, Irene A., additional, Jain, Sarika, additional, Silverman, Paula, additional, Fisher, Carla S., additional, Tevaarwerk, Amye J., additional, Wagner, Lynne I., additional, and Sledge, George W., additional

Published
2022
Full Text
View/download PDF

44. Abstract P1-08-35: Stromal tumor infiltrating lymphocytes analysis by race and ethnicity in triple negative breast cancers from 2 phase III randomized adjuvant breast cancer trials: ECOG-ACRIN E2197 and E1199

Author

Klar, Natalie, primary, Gray, Robert J, additional, Adams, Sylvia, additional, Sparano, Joseph A, additional, Goldstein, Lori J, additional, DeMichele, Angela M, additional, Wolff, Antonio C, additional, Davidson, Nancy E, additional, Sledge, George W, additional, and Badve, Sunil S, additional

Published
2022
Full Text
View/download PDF

45. Prospective Comparison of Geriatric Assessment and Provider’s Assessment of Older Adults With Metastatic Breast Cancer in the Community

Author

Seedor, Rino S, primary, Meeker, Caitlin R, additional, Lewis, Bianca, additional, Handorf, Elizabeth A, additional, Filchner, Kelly A, additional, Varadarajan, Ramya, additional, Hensold, Jack, additional, Padmanabhan, Aruna, additional, Negin, Benjamin, additional, Blankstein, Kenneth, additional, Chawla, Neha R, additional, Song, Wei (Frank), additional, Epstein, Jessica, additional, Winn, Jennifer, additional, Goldstein, Lori J, additional, and Dotan, Efrat, additional

Published
2022
Full Text
View/download PDF

47. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer

Author

Kalinsky, Kevin, primary, Barlow, William E., additional, Gralow, Julie R., additional, Meric-Bernstam, Funda, additional, Albain, Kathy S., additional, Hayes, Daniel F., additional, Lin, Nancy U., additional, Perez, Edith A., additional, Goldstein, Lori J., additional, Chia, Stephen K.L., additional, Dhesy-Thind, Sukhbinder, additional, Rastogi, Priya, additional, Alba, Emilio, additional, Delaloge, Suzette, additional, Martin, Miguel, additional, Kelly, Catherine M., additional, Ruiz-Borrego, Manuel, additional, Gil-Gil, Miguel, additional, Arce-Salinas, Claudia H., additional, Brain, Etienne G.C., additional, Lee, Eun-Sook, additional, Pierga, Jean-Yves, additional, Bermejo, Begoña, additional, Ramos-Vazquez, Manuel, additional, Jung, Kyung-Hae, additional, Ferrero, Jean-Marc, additional, Schott, Anne F., additional, Shak, Steven, additional, Sharma, Priyanka, additional, Lew, Danika L., additional, Miao, Jieling, additional, Tripathy, Debasish, additional, Pusztai, Lajos, additional, and Hortobagyi, Gabriel N., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results